Microbia is an industrial biotechnology research and development specialist. According to DSM, it has developed an effective technology platform that enables it to produce high-quality, natural carotenoids (including β-carotene and canthaxanthin), nutritional products and other specialty materials and chemicals from renewable resources.
“The acquisition of Microbia represents a significant step for DSM in our strategy to accelerate our innovation activities in natural products and fermentation processes,” explained Leendert Staal, president and CEO of DSM Nutritional Products. “This acquisition allows us to expand our product portfolio as well as our research and development capabilities.”
Microbia’s sales are still limited, according to DSM. But the acquisition will allow DSM to incorporate Microbia’s proprietary platform and world class research and development capabilities and support DSM’s ongoing development of the natural carotenoids market.
“We are thrilled to join DSM. Being part of a large global organization, and a world leader in industrial biotechnology, vitamins and carotenoid development, manufacturing and sales will expedite our ability to leverage our proprietary bio-based technology platform,” added Kevin Madden, chief science officer of Microbia. “We look forward to help accelerate DSM’s ongoing efforts to develop, produce and commercialize the next generation of nutritional ingredients and produce more innovative and sustainable products, in a far more cost effective and responsible manner.”